A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

530

Participants

Timeline

Start Date

April 24, 2018

Primary Completion Date

March 21, 2019

Study Completion Date

January 16, 2020

Conditions
Psoriasis
Interventions
DRUG

Mirikizumab

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (69)

100

National Taiwan University Hospital, Taipei

3100

RM Pharma Specialists S.A. de C.V., Distrito Federal

10117

Charité Universitätsmedizin Berlin, Berlin

10508

Chang Gung Memorial Hospital - Linkou, Taoyuan Hsien

10789

ISA GmbH, Berlin

13496

Bundang CHA General Hospital, Sungnam-si

13620

Seoul National University Bundang Hospital, Seongnam-si

14647

Bucheon St. Mary's Hospital, Bucheon-si

15831

Gemeinschaftspraxis Mahlow, Mahlow

16499

Ajou University Hospital, Suwon

19341

Dermatology and Skin Surgery Center, Exton

20246

Universitätsklinikum Hamburg - Eppendorf, Hamburg

21100

Centro Medico del Angel S.C., Mexicali

22143

Clinical Research Hamburg GmbH, Hamburg

23561

Taipei Medical University- Shuang Ho Hospital, New Taipei City

30059

National Taiwan University Hospital Hsin-Chu, Hsinchu

33134

Florida Academic Dermatology Centers, Coral Gables

33624

Forward Clinical Trials, Inc, Tampa

34000

Instituto de Investigaciones Aplicadas a la Neurociencia A.C, Durango

34470

Renstar Medical Research, Ocala

35015

Chungnam National University Hospital, Daejeon

40201

Chung Shan Medical University Hospital, Taichung

44033

Ulsan University Hospital, Ulsan

45190

Instituto Dermatologico de Jalisco Dr. Jose Barba Rubio, Zapopan

46617

The South Bend Clinic, South Bend

48149

Universitätsklinikum Münster, Münster

58249

Clínica Enfermedades Crónicas y Procedimientos Especiales SC, Morella

60008

Arlington Dermatology, Rolling Meadows

61469

Chonnam National University Hospital, Gwangju

70403

National Cheng Kung University Hospital, Tainan City

82140

B&B Investigaciones Medicas, SC, Mazatlán

83301

Chang Gung Memorial Hospital - Kaohsiung, Kaohsiung City

84107

University of Utah MidValley Dematology, Murray

97070

Kohler Milstein Research, S.A. de C.V., Mérida

97223

Oregon Medical Research Center, Portland

98405

Multicare Health System, Tacoma

107076

State scientific centre for dermatovenerology and cosmetolog, Moscow

119991

First Moscow State Medical University n.a. Sechenov, Moscow

170100

Tver State Medical University, Tver'

194021

SPb SBHI Skin-venerologic dispensary #10, Saint Petersburg

214000

GOU VPO 'Smolensk State Medical Academy of Ministry of Health and Social Development of Russian Federation', Smolensk

350000

GBUZ Clinical dermatology and venereological dispensary, Krasnodar

9330871

Shirasaki Clinic, Takaoka-shi

06032

Univ of Connecticut, Farmington

01097

Praxis Gerlach, Dresden

285-8741

Toho University School of Medicine, Sakura Hospital, Sakura

080-0013

Takagi Dermatological Clinic, Obihiro

211-8510

Kanto Rosai Hospital, Kawasaki

236-0004

Yokohama City University Hospital, Yokohama

903-0215

Ryukyu University Hospital, Nakagami-gun

593-8324

Kume Clinic, Nishi-ku Sakai-shi

693-8501

Shimane University Hospital, Izumo

193-0998

Tokyo Medical University Hachioji Medical Center, Hachiōji

141-8625

NTT Medical Center Tokyo, Shinagawa-KU

160-0023

Tokyo Medical University Hospital, Shinjuku-ku

161-8521

Seibo Hospital, Shinjuku-ku

06090

Hospital de Jesus, Mexico City

15-351

NZOZ ZDROWIE Osteo-Medic, Bialystok

90-265

"Dermed Centrum Medyczne Sp. z o.o.", Lodz

21-040

Lubelskie Centrum Diagnostyczne, Świdnik

01-518

Centrum Medyczne AMED, Warsaw

51-318

DermMEDICA Sp. z o.o., Wroclaw

00985

Office of Dr. Alma M. Cruz, Carolina

00909

GCM Medical Group PSC, San Juan

02447

Kyung Hee University Hospital, Seoul

08308

Korea University Guro Hospital, Seoul

03722

Severance Hospital Yonsei University Health System, Seoul

04763

Hanyang University Medical Center, Seoul

05030

Konkuk University Hospital, Seoul

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03482011 - A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter